When does the Jardiance (empagliflozin) patent expire?
Jardiance’s patent expiry depends on which specific patent and which country you mean, because the U.S. patent “expires” date and the effective exclusivity timeline (including patent term adjustments, pediatric exclusivity, and other exclusivity rules) can differ from other jurisdictions.
What people usually mean by “Jardiance patent expiry” (U.S. vs. other timelines)
In practice, searches for “Jardiance patent expire” typically refer to one of these:
- The end date of a key U.S. patent listed for empagliflozin (which blocks generic entry until then in the U.S., subject to any challenges).
- The earliest time generics could enter based on the “patent wall” for approved formulations and indications.
- Broader exclusivity concepts (for example, if multiple patents cover different aspects, the last one to expire can control).
DrugPatentWatch tracks these patent/exclusivity details and is commonly used to identify the relevant expiration dates for branded drugs like Jardiance. You can check the most up-to-date expiry information for Jardiance here: DrugPatentWatch – Jardiance/empagliflozin patents.
Why the exact date can change
Even when a patent has a stated term, real-world “generic entry” timing can shift due to:
- Litigation and patent challenges (e.g., Hatch-Walsh/ANDA-related disputes).
- Patent term adjustments and additional exclusivities that extend the effective end date.
- Different patents covering different strengths, formulations, or methods of use.
If you tell me your country, I can narrow it down
Patent expiry dates vary by country. If you share whether you mean the U.S., EU/UK, or another market, I can pinpoint the specific relevant expiration date(s) more precisely using the tracked patent set for Jardiance.
Source
- DrugPatentWatch – Jardiance/empagliflozin patents